Medicine and Dentistry
Non Muscle Invasive Bladder Cancer
100%
Recurrent Disease
88%
Neoplasm
67%
Bladder
41%
Transitional Cell Carcinoma
33%
Upper Urinary Tract
33%
Bladder Cancer
33%
Radiation Therapy
33%
Biological Marker
33%
Programmed Death 1 Ligand 1
33%
Messenger RNA
33%
Gamma Urogastrone
33%
Epidermal Growth Factor Receptor
33%
Breast Cancer
33%
Immunohistochemistry
33%
Epidermal Growth Factor Receptor 2
32%
Cystoscopy
31%
Urinary Tract
26%
Urine Sampling
21%
Sensitivity and Specificity
13%
Cystectomy
13%
Urinalysis
10%
Muscle Invasive Bladder Cancer
10%
Proportional Hazards Model
9%
Progression Free Survival
9%
Diseases
9%
Chemoradiotherapy
7%
Methylation
6%
Cytotechnology
6%
Fibroblast Growth Factor Receptor 3
6%
Nephroureterectomy
6%
Bladder Irrigation
6%
Immunosuppressive Drug
6%
Mesenchymal-Epithelial Transition
6%
Molecular Profiling
6%
Risk Stratification
6%
Proteomics
6%
Targeted Therapy
6%
Immunotherapy
6%
Cancer Surgery
6%
Tumor Recurrence
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Muscle Invasive Bladder Cancer
100%
Neoplasm
61%
Recurrent Disease
49%
Biological Marker
33%
Programmed Death 1 Ligand 1
33%
Progression Free Survival
7%
Diseases
7%
Tumor Recurrence
6%
Immunotherapy
5%
Immunosuppressive Agent
5%
Immunology and Microbiology
Muscle
100%
Programmed Death 1 Ligand 1
33%
Urine Sampling
26%
Progression Free Survival
9%
Epithelial Mesenchymal Transition
6%
Immunosuppressive Drug
6%
Immunotherapy
6%
Proteomics
6%
Fibroblast Growth Factor Receptor 3
6%
Methylation
6%